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Abstract
Intestinal homeostasis results from complex cross-regulation of signaling pathways; their alteration induces intestinal
tumorigenesis. Previously, we found that the thyroid hormone nuclear receptor TRa1 activates and synergizes with the WNT
pathway, inducing crypt cell proliferation and promoting tumorigenesis. Here, we investigated the mechanisms and
implications of the cross-regulation between these two pathways in gut tumorigenesis in vivo and in vitro. We analyzed
TRa1 and WNT target gene expression in healthy mucosae and tumors from mice overexpressing TRa1 in the intestinal
epithelium in a WNT-activated genetic background (vil-TRa1/Apc mice). Interestingly, increased levels of b-catenin/Tcf4
complex in tumors from vil-TRa1/Apc mice blocked TRa1 transcriptional activity. This observation was confirmed in Caco2
cells, in which TRa1 functionality on a luciferase reporter-assay was reduced by the overexpression of b-catenin/Tcf4.
Moreover, TRa1 physically interacted with b-catenin/Tcf4 in the nuclei of these cells. Using molecular approaches, we
demonstrated that the binding of TRa1 to its DNA target sequences within the tumors was impaired, while it was newly
recruited to WNT target genes. In conclusion, our observations strongly suggest that increased b-catenin/Tcf4 levels i)
correlated with reduced TRa1 transcriptional activity on its target genes and, ii) were likely responsible for the shift of TRa1
binding on WNT targets. Together, these data suggest a novel mechanism for the tumor-promoting activity of the TRa1
nuclear receptor.
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Introduction
The intestinal epithelium is a dynamic tissue that is continuously
renewed through stem cells and committed progenitors, located in
the crypts of Liberku ¨n [1,2]. The balance between proliferation
and differentiation in the crypts is maintained by the fine cross-
regulation among several pathways, including WNT, Hedgehog,
Notch, BMP, and thyroid hormones (THs) [3–6]. These pathways
are key players of intestinal homeostasis, and their deregulation
is correlated with the onset of colorectal cancer [7–9]. The
molecular basis of their action is only partially understood, and the
mechanism of cross-regulation that occurs between these signaling
pathways is still a puzzle. We previously demonstrated that TH
signaling in the mouse intestine is involved in development,
homeostasis and cancer susceptibility [10]#. THs act through
nuclear hormone receptors, the TRs, which are encoded by THRa
and THRb loci [11]. These transcription factors activate or repress
the transcription of target genes by binding to specific DNA
sequences called thyroid hormone response elements (TREs) [12],
and they are involved in several cellular responses, such as cell
proliferation, cell differentiation and apoptosis [5,13]. TH
signaling in the mouse intestine is mediated by TRa1, given that
TRa
0/0 [14] mice as well as hypothyroid mice have reduced cell
proliferation in the crypts during development and in adulthood
[15]. Recently, we showed that the constitutive TRa1 overex-
pression in the intestinal epithelium (vil-TRa1 mice) allows
increased cell proliferation and adenoma development; this
overexpression also enhances the intestinal tumorigenic process
in an Apc mutated genetic background (vil-TRa1/Apc
+/1638N
mice) [9]. Interestingly, one of the molecular features of the vil-
TRa1/Apc mice is the increased activity of the WNT pathway
compared with that of the Apc mutants [9]. This is in agreement
with our previous studies showing that TRa1 activates the WNT
pathway via the transcriptional regulation of the genes Ctnnb1 and
Sfrp2 [15,16].
b-Catenin, the protein encoded by Ctnnb1, was originally
identified as a structural component of cell adhesion complexes
[17]. Upon increased cellular levels and nuclear accumulation, b-
catenin interacts with transcription factors of the T-cell factor (Tcf)
and lymphocyte-enhancer factor (Lef) families [18]. b-catenin/
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WNT signaling pathway. They bind to WNT response elements
(WREs) in the genomic region of target genes involved in cell
proliferation, survival, and migration [7,19]. In the context of the
intestinal epithelium, the b-catenin/Tcf4 complex regulates the
expression of genes involved in the development and proliferation
of normal and malignant epithelia [20,21]. b-catenin, however,
forms complexes with other transcription factors, including
nuclear hormone receptors [22,23]. This interaction modulates
the transcriptional activity of the partners, depending on the
specific tissue or nuclear receptor [24–28]. Our previous studies on
the relationship between WNT and TRa1, combined with these
observations, compelled us to investigate the physical interaction
between TRa1 and b-catenin, the eventual involvement of Tcf4 in
the complex, and its physiopathological relevance.
We established that the increased levels of the b-catenin/Tcf4
complex affects the transcriptional activity of TRa1 in vivo.W e
show that TRa1 interacts with the b-catenin/Tcf4 complex in the
nuclei of Caco2 cells and that this interaction strongly reduces
TRa1 functionality, but has a positive effect on the WNT
downstream response in vitro. Finally, we observed the recruitment
of TRa1 on the WRE regions in pre-cancerous and cancerous
intestinal lesions.
Results
The expression of TRa1 direct target genes is impaired in
vil-TRa1/Apc mice
We analyzed the expression profile of TRa1 target genes in
normal mucosae or tumors from mice of different genotypes to gain
additional insights on the cross-regulation between TRa1a n d
WNT pathways in gut tumorigenesis. Six-month-old vil-TRa1 [9],
Apc
+/1638N [29] and double-mutant vil-TRa1/Apc [9] mice were
analyzed. The vil-TRa1 mice are characterized by hyperprolifera-
tion in the intestinal crypts and a low rate of adenoma development
in the small intestine and colon [9]. The Apc
+/1638N develop a small
number of adenocarcinomas, starting at approximately six months
of age; these tumors occur primarily in the small intestine [29,30]#.
The vil-TRa1/Apc mice develop adenocarcinomas in the small
intestine and colon at a higher frequency than do the Apc mutants.
Moreover, the tumor appearance and progression to invasiveness
are also accelerated in these mice. Finally, WNT activity in the
tumors of these animals is increased compared with Apc mutants
[9].
We compared the expression profiles of Ctnnb1 and Sfrp2,
TRa1-direct target genes [15,16], and of Ccnb1 and Cdc2a,T R a1-
indirect target genes [16]. For Ctnnb1 and Sfrp2, we observed an
increased mRNA levels in the vil-TRa1 mice compared with the
WT mice, while in the normal mucosa or tumors of the Apc mice,
the mRNA levels slightly decreased (Ctnnb1, Figure 1A) or did not
change (Sfrp2, Figure 1B). However, in the vil-TRa1/Apc mice,
the up-regulation of both genes was blunted, and the mRNA level
unchanged (Ctnnb1, Figure 1A) or decreased (Sfrp2, Figure 1B) in
the tumors. When we examined the TRa1-indirect target genes
Ccnb1 and Cdc2a, we observed that TRa1 overexpression
stimulated the mRNA levels of these genes independently of the
Apc mutation (Figure 1C, D). We also analyzed the Ctnnb1 and
Sfrp2 mRNA expression in one-month-old animals. In fact, the
tumorigenic program triggered by the loss of Apc heterozygosis
[30] at that age is not yet accomplished, and the vil-TRa1/Apc
mice do not yet show any signs of mucosal alteration. Interestingly,
the mRNA expression level of TRa1-direct target genes in
these animals was comparable with that of the vil-TRa1 mice, and
in both cases, significantly higher than in the WT intestine
(Figure S1A, B). We excluded the fact that the TRa1-reduced
transcriptional activity is due to a lower availability of hormones,
as the circulating TH level is not altered in the animals of different
genotypes [9]. However, the intracellular concentration of TH
may depend on T3 and T4 metabolism, which is locally regulated
by the iodothyronine deiodinase selenoenzymes (Dio1, Dio2 and
Dio3) [31,32]. Next, we considered the possibility that the
transcriptional activity of TRa1 was reduced by local hypothy-
roidism within the tumors and checked the levels of the three
enzymes. However, when we analyzed the expression of the Dio
mRNAs, we observed that only Dio1 was expressed, and its levels
did not change in the intestine of different genotypes or in the
tumors (Figure S1C), confirming that the cellular context was not
hypothyroid. It is worth noting that in another context, Dio1 has
been shown to be TH-responsive [31]; however, this difference
may be due to the well-described tissue-specific regulation of TH
target genes [10].
The Wnt3a ligand is not sufficient to affect TRa1
transcriptional activity in an ex vivo assay
We used intestinal epithelial primary culture to evaluate
whether activation of the WNT pathway by an agonist could
impair TRa1 transcriptional activity. To selectively modulate
TRa1 and WNT, we treated the cells with T3 and the canonical
Wnt3a ligand [33] alone or in combination. We observed that
T3 and/or Wnt3a increased the number of proliferating cells
(Figure 2A) and expressing nuclear b-catenin [Figure 2B]. The
increase of both activated b-catenin protein level (Figure 2C) and
Ccnd1 mRNA expression (Figure 2D), indicated that the cells were
responding to the simple treatments as previously shown [15,34].
When we investigated the expression of Ctnnb1 and Sfrp2,T R a1
direct target genes, both mRNA levels increased upon T3
treatment, as expected. Wnt3a had no effect on Ctnnb1 mRNA
(Figure 2E) but stimulated Sfpr2 mRNA (Figure 2F). Finally, when
the cells were treated with Wnt3a and T3, the TRa1 targets
behaved as they did when treated only with T3, because they were
not affected by the co-treatment with Wnt3a (Figures 2E, F). The
expression of TRa1 or Tcf4 was not altered by T3 alone or in
combination with Wnt3a (not shown).
Tcf7l2 (Tcf4) is overexpressed in vil-TRa1/Apc mice
The data obtained using the in vitro and in vivo approaches
strongly suggested that b-catenin stabilization induced by Wnt3a is
not sufficient to impair TRa1 transcriptional activity. Thus, the
hypothesis that an increased level of both b-catenin and Tcf4
could affect TRa1 functionality was tested. We examined the
mRNA expression of Tcf4 in the normal intestine and tumors
from animals of different genotypes. The Tcf4 mRNA expression
in vil-TRa1 or the normal mucosa of Apc mice was similar to
that of WT animals (Figure 3A). However, the mRNA level
significantly increased in the normal mucosa of the vil-TRa1/Apc
mice and was even further upregulated in the tumors. We also
observed an increased level of Tcf4 mRNA in the lesions from Apc
mice compared with the healthy mucosa (Figure 3A). This trend
was different from that observed for Lef1 mRNA, another
transcriptional partner of b-catenin in the intestine [35,36]. In
fact, Lef1 mRNA level was significantly increased only in the
lesions independently of the animals’ genotype (Figure 3B).
Finally, we analyzed the expression of Ccnd1 and c-Myc, the
WNT target genes, and we observed their significant upregulation
in the vil-TRa1 and in the normal mucosa of vil-TRa1/Apc mice
compared with that of the WT or the normal mucosa of Apc mice
[Figure 3C, D], in accordance with our previous results [9]. The
expression level of these WNT target genes significantly increased
Cross-Talk between TRa1 and WNT in Intestine
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normal mucosae (Figure 3C, D).
The b-catenin/Tcf4 complex interferes with TRa1
functionality in vitro
The data described above strongly suggested that a negative
feedback loop could occur between TRa1 and the b-catenin/Tcf4
complex. To test this hypothesis, we used a luciferase reporter
system containing a synthetic tandem of TR-binding sites or-
ganized as DR4 (DR4-luc) [15] and monitored its response upon
b-catenin and/or Tcf4 transfection. These experiments were
performed in Caco2 cells maintained in T3-depleted serum with
and without the addition of a supra-physiological concentration of
T3 (Figure 4A). In the control condition, we observed a strong and
significant increase in luciferase activity upon T3 treatment due
to the presence of endogenous TRa1. It is worth noting that we
observed a response to T3 addition in all conditions analyzed
(Figure 4A). The transfection of b-catenin alone did not affect the
DR4-luc response to the endogenous TRa1 stimulated by T3,
while Tcf4 alone slightly reduced the reporter activity. Interest-
ingly, Tcf4 in combination with b-catenin significantly reduced the
T3 response of the endogenous TRa1 compared with the control
(Figure 4A). As expected, the TRa1 transfection in the cells treated
with T3 significantly enhanced the luciferase activity in compar-
ison with the control (Figure 4A). This T3-mediated response in
TRa1-transfected cells was slightly reduced in the presence of b-
catenin, significantly decreased in the presence of Tcf4 and a
stronger negative effect was observed by combining Tcf4 and b-
catenin co-transfection.
We also measured the DR4-luc activity in cells maintained in
culture medium containing physiological concentrations of T3
[37] (Figure 4B). As expected, TRa1 transfection significantly
induced the luciferase activity compared with the control.
Figure 1. Analysis of TRa1 target genes in mice of different genotypes. RT-qPCR experiments were performed in the intestine of 6-month-
old mice of the indicated genotype to analyze the mRNA levels of Ctnnb1 (A), Sfrp2 (B), Ccnb1 (C) and Cdc2a (D). Values represent fold change 6 sd
after normalization to the wild-type [WT] animals. *: P,0.05, **: P,0.001, compared with the WT; #:P ,0.05, ##:P ,0.01 compared with the vil-TRa1
animals, by two-tailed Student’s t-test (n=4). N, normal mucosa; T, tumor.
doi:10.1371/journal.pone.0034162.g001
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with the b-catenin and Tcf4 vectors. The luciferase activity
induced by TRa1 overexpression was not affected by b-catenin
alone but was slightly reduced by Tcf4 (Figure 4B). We decided to
verify if these combinatory transfections could also affect the
activity of the WNT-reporter system TopFlash, which responds to
Figure 2. The Wnt3a ligand is not sufficient to impair TRa1 transcriptional activity ex vivo. The primary cultures of intestinal epithelial
cells were treated with 10 ng/ml of Wnt3a and/or 10
27 M of T3 for 24 hours. (A) The number of proliferating cells in the different experimental
conditions was analyzed by Ki67 immunolabeling; all of the nuclei were labeled by Hoechst. The percentage of Ki67-positive nuclei was determined
by counting under a fluorescence microscope (Zeiss Axioplan). The histograms represent the summary (mean 6 sd) of the scoring of specific
immunolabeling in two independent experiments each conducted in triplicate (n=50). (B, C) Analysis of b-catenin in intestinal epithelial primary
cultures by immunolabelling (B) and WB (C). Cells were in control, T3, Wnt3a and T3+Wnt3a conditions as indicated. Pictures in B show the
fluorescent staining of the nuclei (blue), b-catenin (red) and the merging of each simple labeling. Bar: 15 mm. For the WB (C), we used a specific
antibody allowing the detection of activated non-phosphorylated b-catenin [54,55]. Actin was used as loading control. The image is representative of
two independent experiments. Each lane represents whole protein extracts (50 mg/lane). (D–F) RT-qPCR analysis to evaluate mRNA levels of Ccnd1,
Ctnnb1 and Sfrp2. Results are from three independent experiments, each conducted in duplicate. Values represent fold change 6 sd after
normalization to the control condition (Ctrl). *: P,0.05, **: P,0.01, ***: P,0.001 by two-tailed Student’s t-test (n=6).
doi:10.1371/journal.pone.0034162.g002
Figure 3. Analysis of Tcf7l2 (Tcf4) and Wnt target genes in mice of different genotypes. RT-qPCR experiments were performed in the
intestine of 6-month-old mice of the indicated genotype. (A) Tcf4, (B) Lef1, (C) c-Myc and (D) Ccnd1 mRNA levels were analyzed. Values represent fold
change 6 sd after normalization to wild-type (WT) animals. *: P,0.05, **: P,0.01 compared with the WT; $:P ,0.05, $$:P ,0.01 compared with the
healthy mucosa of the same genotype; @: P,0.05, @@: P,0.01 compared with vil-TRa1/Apc N and T; #:P ,0.05 compared with vil-TRa1, by two-
tailed Student’s t-test (n=4). N, normal mucosa; T, tumor.
doi:10.1371/journal.pone.0034162.g003
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34162Figure 4. b-catenin/Tcf4 complex interferes with TRa1 functionality in luciferase assay in vitro. (A) The DR4-luc luciferase reporter was
transfected into Caco2 cells maintained in T3-depleted serum with or without supplementation with T3 as indicated, together with TRa1, Tcf4 or b-
catenin expression vectors in different combinations. (B, C) The DR4-luc luciferase reporter (B) or TopFlash luciferase reporter (C) was transfected into
Caco2 cells maintained in culture medium containing physiological concentrations of T3, together with the b-catenin/Tcf4 complex in the presence
or absence of the TRa1 expression vector. Histograms represent mean 6 sd from three independent experiments, each conducted in triplicate (n=9).
*: P,0.05, **: P,0.01 compared with the control condition (Ctrl); #:P ,0.05, ##:P ,0.01, compared with the TRa1 condition; $:P ,0.05 compared
with the TRa1+b-catenin condition; ££: P,0.01 compared with the b-catenin or b-catenin+Tcf4 condition, by two-tailed Student’s t-test.
doi:10.1371/journal.pone.0034162.g004
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increase of TopFlash activity when TRa1 was transfected together
with b-catenin or Tcf4 compared with the simple b-catenin or
Tcf4 conditions (Figure 4C). We observed a slight up-regulation of
the TopFlash activity, marginally significant, when TRa1 was
transfected together with b-catenin/Tcf4. We verified the spe-
cificity of these responses by using mutated DR4-luc or FopFlash
reporters (data not shown).
TRa1 binding on chromatin changes during gut
tumorigenesis
Our findings strongly indicated that the increased level of the b-
catenin/Tcf4 complex significantly reduced the TRa1 transcrip-
tional activity both in cell lines and in vivo. To define the
mechanism involved, we evaluated whether TRa1 could physi-
cally interact with b-catenin and/or Tcf4, as has been shown for
other nuclear receptors [22,23]. For this purpose, a co-immuno-
precipitation (Co-IP) approach was employed to selectively target
the endogenous proteins in the nuclei of Caco2 cells. After
validating that TRa1 and b-catenin interact specifically in cell
nuclei (Figure S2), we also analyzed the involvement of Tcf4.
Interestingly, we observed that in the nuclei of the Caco2 cells the
endogenous TRa1 is associated with b-catenin (Figure 5, upper
and middle panels) as well as with Tcf4 (Figure 5, upper and lower
panels). Moreover, all these interactions do not depend on T3
levels.
We then investigated the presence of the three proteins on the
chromatin, by using an in vivo chromatin immunoprecipitation
(ChIP) approach to analyze the TREs and WREs of the specific
target genes of TRa1 and WNT, respectively. The ChIP assay was
performed on WT intestine and the normal mucosa or tumors
from vil-TRa1/Apc mice using anti-TRa1, anti-Tcf4, anti-b-
catenin antibodies or rabbit IgG (as negative control). As shown in
Figures 6A and S3A, in the WT intestine, TRa1 binds to the
promoter region of the Sfrp2 gene, which contains the TRE [16];
however, there was no recruitment of the b-catenin/Tcf4 complex
Figure 5. Physical interaction between TRa1 and the b-catenin/Tcf4 complex. Nuclear extracts from Caco2 cells, maintained in T3-depleted
(2) or T3-supplemented (+) serum, were immunoprecipitated with antibodies directed against endogenous Tcf4, b-catenin or TRa1 and analyzed by
WB by using the antibodies as indicated. Rabbit IgG was used as negative control. Ponceau red was used as whole-protein (50 mg/lane) loading
control. Histone H1 was used to check the enrichment and was the loading control for the nuclear proteins in the inputs. The pictures are
representative of at least three independent experiments.
doi:10.1371/journal.pone.0034162.g005
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(Figures 6A and S3A). This result was similar to that obtained by
an in vitro EMS assay in which TRa1 binds to a DR4 element
without forming a complex with b-catenin and/or Tcf4 (Figure
S4). As the Sfrp2 expression profile suggested, the TRa1 chromatin
occupancy changed between the WT and mutant intestine. In fact,
in vil-TRa1/Apc mice, the TRa1-specific-DNA binding on the
promoter was lost compared with the WT animals (Figures 6A and
S3A). We confirmed this same profile of TRa1 chromatin
occupancy on the Ctnnb1 TRE [15] (Figures 6B and S3B).
Next, we analyzed the specific DNA binding of Tcf4 and b-
catenin on their target genes and the eventual presence of TRa1i n
the same regions. A WRE has been described within the Axin2
promoter [39]. We observed that the Tcf4 occupancy on this
promoter was similar in the different experimental conditions
(Figures 6C and S3C) and that the presence of b-catenin on the
WRE increased during tumorigenesis. More interestingly, TRa1
was not present on the Axin2 WRE region in the WT intestine but
was clearly enriched on it, both in normal mucosae and the tumors
of vil-TRa1/Apc mice (Figures 6C and S3C). We confirmed a
similar trend of TRa1 binding on the WRE region of c-Myc,
another classical direct WNT target [40] (Figures 6D and S3D),
while no specific binding was detected on the Villin or 36B4 gene
promoters (Figures 6E,F and S3E,F). Given the intriguing result of
TRa1 binding to WRE regions, we used the software NUBISCAN
(http://www.nubiscan.unibas.ch) to search for the presence of
putative nuclear receptor binding sites in silico. No TREs were
found within the Axin2 or c-Myc genomic regions containing the
WREs analyzed (data not shown).
Discussion
The process of intestinal maturation and its homeostatic control
by TH-TRa1 in mice results from a complex modulation of genes
and signaling pathways, including the WNT, Notch and BMP
[16]. The WNT pathway is considered a major signaling
modulator of the physiological and pathological cell proliferation
in the intestinal epithelium [41]#. Moreover, due to its direct
action on epithelial stem cells, this pathway is also a main regulator
of epithelial homeostasis [41]. Interestingly, the superfamily of the
Nuclear Hormone Receptors (NHR), to which TRa1 belongs,
displays several levels of functional and physical interactions with
the WNT pathway [22,23]. Although this interaction is relatively
conserved among NHRs, there are however several differences.
Some NHRs, such as VDR, PPARc, and AR, are found in a
complex with both b-catenin and Tcf/Lef, while others, such as
ER and AR, can be found in a complex with Tcf/Lef in the
absence of b-catenin [42–46]. The functional outcomes of these
protein-protein interactions can also differ depending on the
NHR. Generally speaking, b-catenin synergistically activates NHR
activity, and NHR reciprocally deactivates or even represses b-
catenin activity [22,23]. This effect can be attributed to a large
number of mechanisms involving E-cadherin expression, the
competition between Tcf/Lef and NHRs for binding to b-catenin
and/or p300 or the recruitment of co-repressors such as TLE,
NCoR, and SMRT [22,23]. However, these interactions are
highly dependent on the cellular context and can create divergent
effects. For example, PPARc, whose expression and activity is
negatively regulated by WNT in mesenchymal stem cells,
undergoes positive regulation of the WNT signal in colon cancer
cells [45]. A similar phenomenon is reported for VDR, which
super-activates b-catenin activity in keratinocytes [42]#, but
attenuates it in colorectal cancer [25,28,47]. In this context, the
physical interaction between TRa1 and the transcriptional
effectors of WNT was an attractive field of investigation. In fact,
it had been previously shown that TRb1 and b-catenin can
interact directly to form a complex in thyrocytes [24]. This study,
however, did not define the involvement of Tcf4 or the effect on
TRb1 activity. In this study, we have provided the first evidence
that TRa1 interacts with b-catenin. Moreover, this interaction also
involves Tcf4. There are two major differences between the
interaction of TRa1/b-catenin/Tcf4 in the intestinal epithelium
and that of TRb1/b-catenin in thyrocytes. The first is the
destabilization of the TRb1/b-catenin complex by the hormone
T3 [24], while we found no evidence for any T3-mediated effect
on TRa1/b-catenin/Tcf4. The second is the action of the
complex on the WNT pathway. In fact, TRb1 induces the
degradation of b-catenin [24], but TRa1 stabilizes it and activates
WNT [9,15]. It is worth noting that TRa1 and TRb1 often play
opposite roles [5,48], and differences in the cell context may also
explain these divergences.
Previously, we described several levels of complex relationships
between WNT and the TRa1 pathways [10]#. First, we showed
that TRa1 induces WNT activation and enhances cell prolifer-
ation [15,16]. Second, we demonstrated a synergy between these
two pathways during the process of intestinal tumorigenesis [9].
Finally, the third level of regulation outlined herein validates the
positive action of TRa1 on WNT through a protein-protein
interaction. In light of these new results, we propose that an
intriguing feedback loop can also occur and that WNT over-
activation likely decreases TRa1 transcriptional activity (proposed
model of action in Figure 7). However, from our results, we cannot
definitively conclude that this protein-protein interaction involves
only the three partners we analyzed, as other factors that have not
yet been identified may also participate in the complex.
It has been shown that the functional interactions between
signaling pathways involved in gut homeostasis can have a primary
importance in the process of cell transformation. This is the case,
for instance, of the synergy between WNT and Notch [49] or
WNT and TRa1 [9]. In both examples, Notch and TRa1 induce
increased cell proliferation, which is likely to determine an early
mutagenic event in the Apc gene, and finally an acceleration of the
tumorigenic process. We have shown that TRa1 interacts with the
b-catenin/Tcf4 complex and speculate that this interaction might
play a key role during the process of intestinal tumorigenesis by
stabilizing the WNT effectors on their target genes. We could not
observe, however, a clear-cut difference in the expression level of
the WNT targets in the adenocarcinoma of different genotypes.
One possibility is that once the tumoral program is completed, the
molecular differences may be less apparent at the mRNA level. In
addition, colon cancer is genetically heterogeneous and is com-
posed of distinct subpopulations [50,51]. Hence, interpretation of
Figure 6. Chromatin occupancy of TRa1, b-catenin and Tcf4 on genomic regions of target genes. ChIP analysis was performed with
chromatin isolated from the intestine of WT or vil-TRa1/Apc mice (healthy mucosa and tumor) and immunoprecipitated with anti-TRa1, anti-b-
catenin, anti-Tcf4 antibodies or rabbit IgG (negative control). qPCR was performed using specific primers covering the TRE of Sfrp2 (A) and Ctnnb1 (B),
the WRE of Axin2 (C) and c-Myc (D) or the promoters of Villin (E) and 36B4 (F); the Ppia gene was used as internal control. Data are representative of
one of two experiments. Histograms represent the specific-DNA enrichment in each sample immunoprecipitated with the indicated antibody. The
black bar in A–D delineates the threshold of binding specificity determined by the IgG non-specific binding. N, normal mucosa; T, tumor.
doi:10.1371/journal.pone.0034162.g006
Cross-Talk between TRa1 and WNT in Intestine
PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e34162results from a comparative gene expression analysis in whole
tumors can be hampered by such heterogeneity. In support of both
assumptions, an upregulation of the WNT targets in the normal
mucosa of the vil-TRa1/Apc mice is evident and might play a
critical role during the early steps of gut tumorigenesis. With
regard to the direct targets of TRa1, the overexpression of b-
catenin/Tcf4 clearly inhibits their TRa1-dependent upregulation,
but it does not affect the expression of the TRa1 indirect targets
Ccnb1 and Cdc2a. It is probable that other transcription factors
and compensatory mechanism(s) occurring in vivo may also be
responsible for their expression levels.
Our results suggest that the binding of TRa1 to its DNA targets is
shifted to the WNT targets when the b-catenin/Tcf4 protein levels
increase (Figure 7). This condition is typical of intestinal cancers
characterized by mutations in components of the WNT pathway
(including Apc, Ctnnb1 and Axin2) [50,52] that allow for b-catenin
increase and stabilization. With regard to Tcf4 expression, we
observed its upregulation in the tumors of both Apc and vil-TRa1/
Apc mice. Interestingly, we also observed an increased expression of
Tcf4in the normal mucosa of the vil-TRa1/Apc mice but not in the
normal mucosa of the Apc animals. Taken together, our previous
and present datastrongly suggest that even if we refer to ‘‘vil-TRa1/
Apc mice normal mucosa’’, this may only be indicative of the
morphological appearance. Indeed, from a molecular standpoint, it
differs in several ways from the WT mucosa [9] (this paper) and
clearly indicates an altered pre-cancerous status.
In conclusion, we have shown that in the context of intestinal
lesions, TRa1 reshapes its function and induces specific genomic
and non-genomic events. TRa1 transcriptional activity was
negatively modulated by increased levels of b-catenin/Tcf4 and
the binding to its target genes was also impaired. Interestingly,
TRa1 was recruited to WNT target genes specifically within the
lesions. This dual mechanism can have important repercussions
and opens a new perspective in studying the sequential events of
tumor development. An obvious speculation is that b-catenin/
Tcf4 activity on their target genes could be reduced in the absence
of TRa1. Our preliminary results from TRa
0/0/Apc mice sustain
this assumption (our unpublished observations); however, it is
necessary to further confirm this result to account for the delay in
or absence of tumor formation in these animals. A future challenge
will be to define how complex cross-regulation and integrated
networks, such as those involving the NHR and WNT pathways,
can affect the cellular phenotype when signals are altered. These
data will surely be of importance for translational research and
could help explain the contradictory results concerning NHRs and
carcinogenesis.
Materials and Methods
Animals and sample collection
We used vil-TRa1, vil-TRa1/Apc, Apc
+/1638N and wild-type
animals [9]. Mice were housed and maintained with approval
Figure 7. Proposed molecular model for the action of TRa1 in controlling the WNT signaling pathway in the intestine. In physiological
conditions (WT), TRa1 binding on TREs positively regulates the expression and stabilization of b-catenin, and then contributes to maintaining tissue
homeostasis. In vil-TRa1 mice, there is an increased level of b-catenin expression and stabilization that leads to WNT activation and hyper-
proliferation. In vil-TRa1/Apc mice, the stronger b-catenin stabilization and Tcf4 overexpression might be responsible of the shift in TRa1 binding
from TREs to WREs. The physical interaction between TRa1 and b-catenin/Tcf4 we showed can explain its presence on the WREs. We speculate that
this is a novel mechanism of WNT induction promoting the activation and/or the acceleration of the tumorigenic process. TREs, Thyroid hormone
response elements; WREs, WNT response elements. Solid lines indicate genomic actions; dotted lines represent the speculative model of a negative
regulatory loop involving non-genomic actions and eventually other(s) factor(s). Double black arrows indicate crypt width in WT and vil-TRa1
intestinal sections.
doi:10.1371/journal.pone.0034162.g007
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Supe ´rieure de Lyon (Lyon, France) and in accordance with
European legislation on animal care and experimentation. Lyon
University’s ‘‘Comite ´ d’Evaluation Commun au Centre Le ´on
Be ´rard, a ` l’Animalerie de transit de l’ENS, au PBES et au
laboratoire P4’’ (CECCAPP) and the ‘‘the Comite ´R e ´gional
d’Ethique pour l’Expe ´rimentation Animale» (CREEA) approved
all animal studies (agreement no. 0230). Animals were sacrificed,
and the intestine (normal mucosae and tumors) was quickly
removed. We recovered tumors and normal portions of the
mucosa under a binocular microscope (Olympus) and froze them
in liquid nitrogen for RNA extraction or the ChIP assay.
Intestinal epithelium primary cultures, immunolabelling
and western blot
Intestinal epithelial primary cultures were derived from 4–6 day
old neonatal mice according to Evans and colleagues [53]. Briefly,
after sacrifice, the entire small intestine was removed. The
epithelium was isolated as intact organoids by enzymatic dis-
sociation using collagenase type XI (Sigma) and dispase (Boehrin-
ger Mannheim), followed by physical disaggregation and filtration
on gauze. Organoids were plated in Dulbecco’s modified Eagle
medium (DMEM, Invitrogen) supplemented with 2.5% heat-
inactivated fetal calf serum (Gibco), 20 ng/ml epidermal growth
factor (Sigma), and insulin-transferrin-selenium diluted 1/100
(Sigma). Culture surfaces were coated with Matrigel
TM Basement
Membrane Matrix (BD Biosciences). For immunolabeling exper-
iments, cover-slips were inserted in the wells before coating. For
proliferation studies, 10 mM BrdU was added to the culture
medium for an overnight incubation. The purity of the epithelial
colonies was analyzed by immunolabeling for specific markers:
epithelial cells: anti-cytokeratins (ICN); fibroblasts: anti-vimentin
(Sigma); smooth muscle cells: anti-smooth muscle actin (Sigma).
For treatment experiments, after 2 days of culture, the vehicle
alone or 10
27 M T3 and/or 10 ng/ml of recombinant Wnt3a
(R&D system) was added to the culture medium for 24 hours.
Immunolabeling was performed on 2% paraformaldehyde-fixed
cultures, as previously described by Rezza and colleagues [32]. We
used anti-Ki67 (Labvision MBL) and anti-b-catenin (Santa Cruz)
primary antibodies.
Western blot (WB) was performed on whole-protein extracts
obtained by homogenizing the samples in RIPA buffer, as
described in [32]. Whole protein extracts (50 mg/lane) from cells
maintained in the different experimental conditions were ana-
lyzed. We used anti-activated b-catenin (Upstate) and anti-actin
(Sigma).
Cell lines and transfection experiments
This study was performed on the human Caco2 colorectal
cancer cell line (from the American Type Culture Collection).
Caco2 cells (50,000 cells/well in 24 multiwell plates) were cultured
in DMEM supplemented with 10% heat- inactivated fetal calf
serum. We used the following vectors: pGl2-DR4-Luc and pGl2-
mutDR4-Luc (200 ng/well) and pGS5-TRa1 [15] (100 ng/well);
TopFlash and FopFlash (Upstate; 200 ng/well); pCIneo-b-cate-
ninXL (100 ng/well), Evr2-Tcf4E (100 ng/well; kind gift of
Professor Waterman, UC Irvine, USA); pRL-CMV (1 ng/well;
Promega). The vectors were transfected using the Exgen
transfection reagent (Euromedex). For the T3 treatments, the
cells were maintained in thyroid hormone-depleted serum [35].
T3 (10
26 M) or vehicle alone was added to the culture medium
24 hours before the end of the culture. Luciferase activity was
measured 48 hours after transfection using the luciferase dual
system (Promega).
Coimmunoprecipitation assay and western blot analysis
Coimmunoprecipitation (CoIP) studies were conducted on
Caco2 cells using a slightly modified procedure described by
Guigon and colleagues [24]. Nuclear and cytoplasmic extracts
were pre-cleared with Protein A magnetic beads (Invitrogen) for
4 hours at 4uC. Immunoprecipitations of endogenous complexes
were conducted overnight at 4uC with anti-Tcf4 (Santa Cruz),
anti-b-catenin (Santa Cruz), anti-TRa1 [15] antibodies. As
negative controls, the extracts were incubated with rabbit IgG
(Promega). The complexes were washed and then recovered with
Protein A magnetic beads. Immunoprecipitated proteins were
subjected to SDS-PAGE and western blot analysis by using the
different antibodies mentioned above. Whole proteins (50 mg/
lane) on the blots were stained with Ponceau red. The nuclear
extracts and loading in inputs were examined by using an anti-
Histone H1 antibody (Santa Cruz).
RNA extraction and RTqPCR analysis
RNA was extracted from tissue samples using the Qiagen
RNeasy Kit (Qiagen). To avoid the presence of contaminating
DNA, DNase digestion was performed on all preparations.
Reverse transcription was performed using MuMLV reverse
transcriptase (Promega) on 1 mg of total RNA using random
hexanucleotide priming (Promega) according to the manufactur-
er’s instructions. For the primary cultures, RNA was extracted
using the Absolutely RNA Nanoprep Kit (Stratagene). Reverse
transcription was performed using the SuperScript III First-Strand
Synthesis SuperMix for qRT-PCR (Invitrogen) on 300 ng of total
RNA. All of the cDNA samples were purified using the Qiagen
PCR Purification Kit (Qiagen) before use for the qPCR
experiments. The qPCR was performed with SYBR green PCR
master mix (Qiagen) in an MxP3000 apparatus (Stratagene). The
data from the qPCR were normalized to 36B4 levels for each
sample. The primers are listed in Table S1A.
Electrophoretic mobility shift assay (EMSA)
Tcf4, b-catenin, TRa1 and RXRa full-length cDNAs were
transcribed/translated in vitro using the quick TNT kit (Promega)
according to the manufacturer’s protocol. We performed the
EMSA assay on the DR4-radiolabeled probe, as previously
described [18], in a buffer similar to that of the CoIP: 3%
glycerol, 20 mM HEPES, 3 mM DDT, 0.3% NP40, 100 mM
KCl, protease inhibitor cocktail (Roche), 4 mM spermidine, and
poly-dI-dC (1.5 mg). Where indicated, anti-TRa1 [15] and anti-
Tcf4 (Santa Cruz) antibodies were included in the reaction mix.
Chromatin immunoprecipitation (ChIP)
The ChIP study was performed on 10 mg of samples collected
from the intestine of vil-TRa1/Apc (healthy mucosa and tumors)
and WT mice. The samples were minced with a razor blade and
crosslinked with 1% formaldehyde at room temperature for
15 minutes. The crosslinking reaction was stopped by the addition
of glycine to a final concentration of 0.125 M, and the samples
were incubated at room temperature for 5 minutes. The samples
were then centrifuged at 200 g to pellet the pieces. The fragments
were washed once in cold PBS containing protease inhibitor
cocktail (Roche) and then disaggregated by 10 strokes in a Dounce
homogenizer. The resulting homogenate was centrifuged at
2000 g, the pellet recovered was then incubated in SDS buffer
(1% SDS, 50 mM TRIS pH 8.1, 10 mM EDTA) on ice for
10 minutes. After 15 minutes of sonication (30 sec on/30 sec off
cycles, Biodisruptor), the samples were centrifuged at maximum
speed at 4uC, and the supernatant was recovered and quantified
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Technologies). The same amount of each sample was diluted 1:10
in dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM
EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl). After pre-
clearing with Protein A magnetic beads (Invitrogen), each sample
was divided into four samples, and the precipitation was
performed using 9 mg of each antibody (anti-Tcf4, Santa Cruz;
anti b-catenin, Santa Cruz; anti-TRa1 [15] or rabbit IgG). At the
end of the reaction and washing steps, the complexes were
recovered using protein A magnetic beads. The DNA was
extracted after Proteinase K (Fermentas) and phenol-chloroform
treatments. Specific DNA fragments were analyzed by qPCR
using a SYBR green PCR master mix (Qiagen) in an MxP3000
apparatus (Stratagene). The primers designed to amplify the
genomic regions containing: 1) TREs we previously described
[15,16]; 2) WREs described in literature [39,40]; and 3) the villin
and Rplp0 (36B4) promoters, as negative controls [15]. Primer
sequences are listed in Table S1B; the Ppia gene was used in all
reactions as internal control.
Supporting Information
Figure S1 RT-qPCR analysis in mice. (A, B) Analysis of
TRa1-direct target genes in 1 month-old WT, vil-TRa1 and vil-
TRa1/Apc mice. RT-qPCR analysis was performed to evaluate
the mRNA levels of Ctnnb1 and Sfrp2. Values represent fold
change 6 sd after normalization to the wild-type (WT) animals.
*: P,0.05, **: P,0.01 compared with the WT by two-tailed
Student’s t-test (n=4). (C) Analysis of iodothyronine deiodinase
selenoenzyme type 1 (Dio1) mRNA expression in WT, vil-TRa1,
Apc and vil-TRa1/Apc mice. RT-qPCR experiments were
performed in the intestine of 6-month-old mice. Values represent
specific mRNA expression 6 sd after normalization to 36B4
(n=4). N, normal mucosa; T, tumor.
(PDF)
Figure S2 Physical interaction between TRa1 and the b-
catenin in nuclei. Cellular lysates from Caco2 cells, maintained
in T3-depleted (2) or T3-supplemented (+) serum, were
fractionated into nuclear (N) and cytoplasmic (C) extracts. Lysates
were immunoprecipitated with antibodies directed against endog-
enous b-catenin (upper panel) or TRa1 (lower panel), and the WB
analysis of the indicated proteins was performed. Rabbit IgG was
used as negative control. Ponceau red was used as whole-protein
(50 mg/lane) loading control. Histone H1 was used to check the
enrichment and was the loading control for the nuclear proteins in
the inputs. The pictures are representative of at least three
independent experiments.
(PDF)
Figure S3 Chromatin occupancy of TRa1, b-catenin and
Tcf4 on genomic regions of target genes. ChIP analysis was
performed with chromatin isolated from the intestine of WT or vil-
TRa1/Apc mice (healthy mucosa and tumor) and immunopre-
cipitated with anti-TRa1, anti-b-catenin, anti-Tcf4 antibodies or
rabbit IgG (negative control). qPCR was performed using specific
primers covering the TRE of Sfrp2 (A) and Ctnnb1 (B), the WRE
of Axin2 (C) and c-Myc (D) or the promoters of Villin (E) and
36B4 (F); the Ppia gene was used as internal control. Histograms
represent the specific-DNA enrichment in each sample immuno-
precipitated with the indicated antibody. The black bar in A–D
delineates the threshold of binding specificity determined by the
IgG non-specific binding. N, normal mucosa; T, tumor.
(PDF)
Figure S4 Electromobility Shift Assay on DR4 response
element. (A) EMSA analysis was performed to examine the
TRa1/b-catenin/Tcf4 complex formation on a DR4-radiolabeled
probe. In vitrotranscribed/translated proteins were added to the
mixture as indicated, and the DNA-protein complexes were
separated by native gel electrophoresis. Specific antibodies were
added to assess the protein[s] involved in the complex. In all of the
conditions, only TRa1 alone binds to the labeled probe. (B) EMSA
performed in the presence of the TRa1 transcriptional partner
RXRa. It is worth noting that even in the presence of RXRa,
there is no b-catenin/Tcf4 binding to TRa1 on a TRE.
(PDF)
Table S1 (A) Oligonucleotides used for the RT-qPCR study. (B)
Oligonucleotides used for qPCR study after ChIP assay.
(PDF)
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